Share on StockTwits

InterMune (NASDAQ:ITMN) saw some unusual options trading activity on Monday. Traders bought 5,253 call options on the company, Analyst RN reports. This is an increase of approximately 156% compared to the typical volume of 2,052 call options.

In other InterMune news, EVP Paul D. Arata sold 7,500 shares of the company’s stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $50.00, for a total transaction of $375,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

ITMN has been the subject of a number of recent research reports. Analysts at Jefferies Group upgraded shares of InterMune from an “underperform” rating to a “hold” rating in a research note on Monday. They now have a $74.00 price target on the stock, up previously from $25.00. Separately, analysts at William Blair raised their price target on shares of InterMune from $55.00 to $74.00 in a research note on Monday. Finally, analysts at Stifel Nicolaus downgraded shares of InterMune from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $53.00 price target on the stock, down previously from $53.80. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. InterMune has an average rating of “Buy” and an average price target of $55.75.

InterMune (NASDAQ:ITMN) traded up 35.41% on Monday, hitting $72.85. The stock had a trading volume of 51,531,472 shares. InterMune has a one year low of $10.95 and a one year high of $55.24. The stock’s 50-day moving average is $45.86 and its 200-day moving average is $36.13. The company’s market cap is $7.866 billion.

InterMune (NASDAQ:ITMN) last released its earnings data on Wednesday, August 6th. The company reported ($0.72) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The company’s quarterly revenue was up 141.2% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.75 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Receive News & Ratings for InterMune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterMune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.